🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Renal Cell Carcinoma
Clinical trial register · United States · industry-sponsored

Renal Cell Carcinoma Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 19 New York 10 Florida 9 Massachusetts 9 Texas 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC5 Exelixis3 Bristol-Myers Squibb2 HiFiBiO Therapeutics2 Daiichi Sankyo1
State
California19 New York10 Florida9 Massachusetts9 Texas9
All 36 states
Target enrolment
to
27 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682Renal Cell Carcinoma
Bristol-Myers Squibb
Phase 1
281
Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-01-15
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Illinois, Michigan, Nebraska, New York, South Carolina, Texas
2025-12-19
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
California, Florida, Texas, Washington
2025-09-26
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
140
California, New York, North Carolina, Pennsylvania, Tennessee
2025-07-20
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Not yet open
Delving Into Participation Trends in Renal Cell Carcinoma Studies
NCT06093568Renal Cell Carcinoma
Power Life Sciences Inc.
Observational
500
California
2024-11
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
Nammi Therapeutics Inc
Phase 1
100
California, Colorado, Georgia, New York, Texas, Wisconsin
2024-08-28
Recruiting
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605Renal Cell Carcinoma
HiberCell, Inc.
Phase 1
80
Arizona, California, Colorado, Connecticut, Minnesota, Missouri, New York, Ohio
2024-04-29
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 2
272
California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas
2024-04-10
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
Alabama, California, Georgia, Maryland, Tennessee, Texas
2023-04-21
Active, closed
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Janux Therapeutics
Phase 1
130
California, Georgia, Illinois, Michigan, Missouri, New York, North Carolina, Ohio
2023-04-19
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
60
District of Columbia, Illinois, Massachusetts, Utah
2022-08-10
Active, closed
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05238883Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
HiFiBiO Therapeutics
Phase 1
72
Arizona, California, Florida, Minnesota, Missouri, Texas, Virginia
2022-03-10
Recruiting
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
VastBiome
Observational
800
Kentucky
2021-11-22
Recruiting
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
Simcha IL-18, Inc.
Phase 1/2
316
Arizona, Colorado, Connecticut, Florida, Massachusetts, New York
2021-08-06
Active, closed
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
NCT04707248Renal Cell Carcinoma, Ovarian Tumor
Daiichi Sankyo
Phase 1
179
Arizona, Colorado, Florida, Oklahoma, Tennessee
2020-12-22
Active, closed
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219Renal Cell Carcinoma
Exelixis
Phase 3
855
California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts, Michigan
2019-06-25
Active, closed
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402Renal Cell Carcinoma
Bristol-Myers Squibb
Phase 3
437
District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina
2019-06-21
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Exelixis
Phase 1
325
California, Florida, Georgia, Iowa, Kansas, Maine, Maryland, Massachusetts
2019-03-20
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
NCT03592472Renal Cell Carcinoma
Xynomic Pharmaceuticals, Inc.
Phase 3
413
Arizona, California, Kentucky, Louisiana, Nebraska, New York, Ohio, Oregon
2018-07-17
Rows per page Showing 1–25 of 27
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/renal-cell-carcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.